Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
God bless, President Donald Trump! Streamlining the FDA-approval process would get the ball rolling on SequestOX.
Cheers!
Wow, I never saw this much action in a while.
Cheers!
Make Elite Great!
SequestOX 2017!
Cheers!
Cheers!
Cheers!
Let's keep it up, guys. Elite has more value to offer all investors.
Cheers!
Cheers!
Just RnR. Elite should be poised for another upward run given the latest news.
Cheers!
SequestOX 2017!
Cheers!
Cheers!
A thousand "Cheers!" to our new ANDA.
Cheers!
Folks still see value when ELTP traded in the 13-cents range. While Trump will make America great, Hakim will make Elite great!
Cheers!
Got my kalua turkey and poi ready. If ELTP goes to 4-cents/share, it would be a great luau.
Cheers!
Elite = Profit On Shares
Save your money and be patient when ELTP is on sale.
Cheers!
That would be a guaranteed approval for SequestOX to make Elite great.
Cheers!
Elite 2017!
Cheers!
Trump just dropped a big hint to the pharmaceutical industry
By Carolyn Y. Johnson November 14 at 10:37 AM
President-elect Donald Trump speaks to the media after a meeting with Senate Majority Leader Mitch McConnell (R) at the Capitol. (Nicholas Kamm/AFP via Getty Images)
A single sentence in President-elect Donald Trump's health-care platform sends a strong hint to the drug and medical device industry that they may have an easier time getting their products on the market under his administration.
“Reform the Food and Drug Administration, to put greater focus on the need of patients for new and innovative medical products,” his health plan states.
On the face of it, the bullet point may seem almost bland, but efforts to integrate patients' preferences and encourage innovation often result in proposals aimed at speeding up the process for getting new medicines on the market by easing regulations. Critics argue that such efforts can erode standards that are in place to protect patients from drugs that don't work and might even be harmful.
“The language … is industry code for deregulation and reducing of safety standards,” said Robert Weissman, president of Public Citizen, a consumer watchdog. “Of course, the general deregulatory rhetoric from candidate Trump is a worry for us, but as applied to FDA, it would be very troubling.”
[Winners and losers in the health-care industry under President Trump]
No one is sure about the precise direction of policy under the Trump administration. But the idea of faster approval of medicines and devices has been popular, meaning this may be one of Trump's health-plan goals to gain support from both sides of the aisle. The drug industry, which had been preparing to defend its business model and pricing under a possible Hillary Clinton presidency, may now see an opportunity instead to streamline the drug-approval process, which companies have complained can be onerous, bureaucratic and a barrier to competition.
Stephen Ubl, president and chief executive of PhRMA, the trade group for the drug industry, emphasized in a statement the importance of solutions that “enhance the private market.”
“We are in a new era of medicine with treatments and cures that are completely transforming the fight against debilitating diseases,” Ubl said. “To ensure this innovation continues, we need to modernize the U.S. Food and Drug Administration to keep pace with scientific advances, remove regulatory barriers that make it harder to move to a value-driven health care system and focus on making better use of the medicines we have today.”
Wonkbook newsletter
Your daily policy cheat sheet from Wonkblog.
Sign up
FDA spokeswoman Jennifer Rodriguez said in an email that the agency “stands ready to work with the incoming administration to protect public health by assuring the safety and efficacy of investigational medical products.”
Mark McClellan, director of the Duke-Margolis Center for Health Policy, said that at a time when there is deep division on many health-care issues, streamlining the process at the FDA may be a rare bit of common ground.
But it may be unwise to read too much into the sentence, given Trump's unpredictability — and the lack of certainty about who will define his health policy.
“I think the honest answer is nobody knows” what to expect, said Diana Zuckerman, president of the National Center for Health Research. “Some members of Congress owe pharma a favor; we don’t know the Trump campaign is in that position, and they might not be — and that might give them a certain amount of flexibility. The Trump campaign is nothing if not iconoclastic.”
And Weissman thinks that the upturn in biotech and pharmaceutical company stocks after the election may have been overly optimistic. Trump has talked about drug prices as a problem and even said he supported Medicare being allowed to negotiate drug prices — a position the industry opposes. Even if pricing is off the table, the Affordable Care Act extended insurance to millions of Americans who could then get easier access to prescription drugs — and it's unclear exactly what would replace it. The pocketbook problem of paying for prescriptions won't go away for people across the country, Weissman points out — which could keep the heat on politicians to do something about prices.
Cheers!
Been busy to get Trump elected, and he will be great for ELTP. Sending a big shoutout to investors who bought shares today.
Cheers!
I strongly doubt Elite has the funds to pay he/she. ELTP would start to move up as soon as we hear news updates on ELI-200 or other new drug developments. There is sufficient "rocket fuel" to move this stock higher.
Cheers!
Nice article on Elite Pharma. Cheers!
Really low volume. Can't interpret much into it.
Cheers!
You are supposed to buy undervalued stocks and sell high. I swing trade and invest long-term.
Cheers!
Indeed, ELTP is still a great value stock. It takes an investor with a strong stomach to endure the roller-coaster ride and the unpredictability of the FDA's decisions.
Cheers!
Looks like the major indices are just down. ELTP will move up in a few day(s).
"Cheers!" from Budapest, Hungary!
It is like living on an active volcano. You would hear and feel the rumblings until a "seismic" event sends the ELTP share price higher.
"Cheers!" from Lucerne, Switzerland!
ELTP will fly and soar. There are more drugs and approvals in her future. FDA disapprovals are part of the game, but that does not mean would not have her share of success.
Cheers!
Running with some friends and representing Elite Pharma in the 2016 Berlin and Budapest Marathons. Just landed in LAX and catching a connecting flight to Berlin. Wish me luck!
Cheers!
Longs have spoken.
Cheers!
Talking about being stuck between a rock and a hard place, we have two hurricanes bearing down towards Hawaii, and then Obama landing today that would cause some traffic gridlock. Nevertheless, ELTP would have her day in the sun.
Cheers!
Well, if we thought ELTP is a scam we would not be wasting time to sharing and posting our due diligence and opinions. But there is more to Elite than meets the eye.
Cheers!
Once the FDA finally approved SequestOX, this would remove all doubts and put Elite on track to engage in its strategic objectives.
Cheers!
The sky is the limit for ELTP. Cannot post much since I am planning for my trip to Europe: Berlin, Vienna, Florence, Lucerne, and Budapest in September-October.
Cheers!
The share price will be floating at these levels until we receive news on SequestOX. A great opportunity to add shares. Good luck and Cheers!
I do like spam with my rice. Elite will get the TMAX resolved.
Cheers!
Today is Hawaii 5-0 Day in Hawaii! Long-term ELTP since 2011.
Cheers!
Any evidence of a slide down? Elite is generating revenues and developing new drugs. Although it would not be easy, FDA-approval will come for SequestOX.
Cheers!
Once Elite receives FDA-approval for its SequestOX, it is a whole new ball game. Meanwhile, its diversified non-ADT/ART drug pipeline continues to earn more revenues.
Cheers!
Yup, the only way to backup one's talk is to have skin in the game. SequestOX has Hakim's signature written all over it, and he would do everything in his power to see that the FDA would not say, "No", a second time.
Cheers!
ELTP = ENORMOUS LONG TERM PROFITS
Cheers!
Aqua would cut in line to steal shares.
Cheers!